DELEX HEALTHCARE GROUP

Business Activities

Delex Healthcare Group Inc. (DELEX) was incorporated in 2017 in Delaware, USA. DELEX is engaged in the development and distribution of pharmaceutical and healthcare products through its subsidiaries, Delex Pharma International Inc. (Delex Pharma), DLX Holdings, Corp., and JMN Brother’s Pharma Limited, Inc.

DELEX Pharma International, Inc. (Delex Pharma) was incorporated in 2010 in Manila, Philippines. Delex Pharma currently has over 100 sales and marketing teams and over 1,000 distribution channels including hospitals, pharmacies, and healthcare centers across the country.

SB SHARES IN DELEX

300,000,000

PROJECTED SHARE VALUE

$150m Year 5 | $200m Year 6

WEBSITE

www.delexhealth.com

Delex aims to close the gaps that many patients experience in coping in the ICU (Intensive Care Units) from their health conditions to the high cost of treatments and medicines by providing quality alternative drugs at affordable prices. Over the years, Delex has develop the Strengths and Advantages stated below:

1) Strong Corporate Performance

Ranked 3rd among all National Companies in the Hospital Sector.
Ranked 49th in the Philippine Pharmaceutical Industry (based on IQVIA Mat Ref Dec 2020 Report).

2) 5 Company Owned Brands with Approved Trademarks

Delex Pharma has received Trademark Approval from the Intellectual Property Office of the Philippines (IPOPH) for 5 of its owned brands – Ceftrex, Delexam, Delexard, Dobulex and Norepin.

3) 5 Company Owned Brands for Global Markets

Delex Pharma owns the patents and production rights for 5 pharmaceutical products – Ceftazin, Ceftrex, Dobulex, Nicardilex and Norepin. Delex plans to market these products globally, and further develop more product range, its distribution and markets across the world, after its fundraising and or public listing.

4) 4 Products Listed in the Top 200 Hospital Ethical Products

4 of the products distributed by Delex Pharma are listed in the Top 200 Hospital Ethical Products, namely: Norepin, Ifimol, Nicardilex and Dobulex.

5) 2 Products with 90% Market Penetration

2 of the products distributed by Delex Pharma – Norepin and Ifimol, have approximately 90% market penetration to the hospitals in the Philippines. Norepin is steadily becoming the market leader in the pharmaceutical market and has been ranked 7th among the top 200 products in the pharmaceutical industry. Ifimol is currently the market leader in the I.V. Paracetamol market.

6) 9 Top Leading Brands and Market Leaders

9 of the products distributed by Delex Pharma – Dobulex, Endurpin, Funginil, Ifimol, Intrafen, Midazolex, Nicardilex, Norepin, and Totilac are top leading brands and market leaders in their respective therapeutic sectors in the Philippines.

7) 16 Available Product Lines

Delex Pharma currently distributes a total of 16 product lines covering critical care, anesthesia, and anti-infectives, (excluding its device business), mainly for intensive care settings such as Intensive Care Units, Emergency Rooms, and Operating Theaters.

8) Certificates of Product Registrations for Various Products

Delex Pharma holds Certificates of Product Registrations for 5 Critical Care Drugs: Dobulex (Dobutamine), Humal (Human Albumin), Nicardilex (Nicardipine Hydrochloride), Norepin (Norepinephrine), and Totilac (Hypertonic Lactate); 5 Anti-Infectives: Ceftazine (Ceftazidime), Ceftrex (Ceftriaxone), Delexigyl (Metronidazole), Funginil I.V. (Fluconazole), and Linezolid (Axazolid); and 6 Anesthesias: Endurpin (Nalbuphine Hydrochloride), Ifimol I.V. (Paracetamol), Intrafen (Ibuprofen), Keterolex (Keterolac Trometamol), Midazolex (Midazolam), and Tramadex (Tramadol); and several medical devices.

9) FDA Licenses and Permits

Delex Pharma currently holds various licenses and permits issued by the Philippines Food and Drug administration for (i) Importer/ Wholesaler/Distributor of Drugs (ii) Importer of Medical Devices (iii) Food Wholesaler, (iv) Cosmetic Importer and Wholesaler and (v) Drugstore Operator, including Online Order and Delivery.

10) Strong Marketing with over 5,000 Distribution Channels

Delex Pharma distributes its products to over 5,000 distribution channels including private and government hospitals, drugstore chains, sub-distributors, clinics, dispensing HCPs, etc.

11) Established Parties for Projects and Services

Delex Pharma has appointed several established parties for its various projects and services:

ISO 9001-2015 Certification from CPG.
SGV; member firm of Ernst & Young as its external auditor from 2020.
Isla Lipana & Co; member firm of PwC as its external auditor from 2013 to 2019.
Isla Lipana & Co; member firm of PwC on Project Fleming to ensure business stability.
KPMG on Project Apollo to improve the company’s internal business processes mainly in Distribution, IT and Finance.

12) Awards & Recognitions

Diversity Company of the Year for 2020 – awarded by Asia CEO Awards.
Philippines Best Brand for 2019 – awarded by CMO Asia.
SME Company of the Year – awarded by Asia CEO Awards.
Executive Leadership Team of the Year for 2017 – awarded by Asia CEO Awards.
Delex Pharma’s Chairman of the Board and CEO, J. de Ruyter Oroceo was awarded:
Global Filipino Executive of the Year for 2020 – awarded by Asia CEO Awards
Delex Pharma’s VP for Marketing, Lourdes Monasterio was awarded:
Pioneering Woman Leader for 2020 – awarded by CMO Asia.
Philippines Women Leader’s Award for 2019 – awarded by CMO Asia.

13) Training and Network with Healthcare Professionals

Delex University was established to continuously provide seminars, updates and tools for its employees and external customers. Delex has successfully conducted over 200 ICU Forums and Webinars with over 160,000 viewers.

Delex has also built a database of 100,000 HCPs (Healthcare Providers) from 96 countries since May 2020. This was made possible by partnering with 30 medical societies and hospitals through its online forums and webinars.

14) US$1.5 Trillion Global Pharmaceutical Market

The global pharmaceutical market is around US$1.5 trillion in 2022. Worldwide pharmaceutical revenue had seen a steady increase every single year since 2001, when the market’s value was about two-thirds smaller. The largest submarket within this industry has been the United States in recent years. Total pharmaceutical sales in the United States amounted to over $600 billion, according to estimates as of Q3 2022.

15) US$260 Billion Asian Pharmaceutical Market

According to Global Pharma sales projections for 2025, Southeast Asia and East Asia, excluding Japan and China, will report consolidated sales of over $260 billion, putting the subregion in third place behind North America and the European Union. All major Southeast Asian pharma markets were forecasted to experience medical sales growth in the next few years.